Research Article
Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity
Table 2
Clinical, biochemical, and imaging parameters of normal BMI patients with T2DM and visceral adiposity before and after exenatide or humalog Mix25 intervention.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ALT: glutamic pyruvic transaminase; AST: glutamic oxalacetic transaminase; BMI: body mass index; DBP: diastolic blood pressure; FGF-21: fibroblast growth factor 21; FINS: fasting insulin; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; HOMA-β: homeostasis model assessment of β-cell function; HOMA-IR: homeostatic model assessment of insulin resistance; LFC: liver fat content; MBCI: modified β-cell function; SAT: subcutaneous and visceral adipose tissue; SBP: systolic blood pressure; TC: total cholesterol; TG: triglycerides; VAT: visceral adipose tissue; WC: waist circumference; 2hFBG: 2 h plasma blood glucose. Data are expressed as the or median (interquartile range). |